Development of a novel RNA-based microsatellite stable predictive response signature (MSS-PRS) to identify MSS colorectal cancer (CRC) patients with a microsatellite instability-high (MSI-H) molecular phenotype

被引：0
|
作者：
Pappan, Kirk
Mayhew, Gregory
Shepherd, Jonathan
Guo, Yuelong
Beebe, Kirk
Eisner, Joel
Milburn, Michael
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-1040
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1040
引用
收藏
页数：2
相关论文
共 43 条
  • [1] Comparative analysis of the tumor immune microenvironment (TIME) in primary and metastatic sites of microsatellite stable (MSS) and microsatellite instability-high (MSI) colorectal cancer
    Fakih, M.
    Ye, J.
    Wang, C.
    Egelston, C.
    Huang, M.
    Mercer, J.
    Thompson, M. A.
    Gong, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S422 - S422
  • [2] Humanized patient -derived xenografts (PDXs) recapitulate clinical responses in microsatellite stable (MSS) and unstable (MSI-H) colorectal cancer (CRC)
    Capasso, Anna
    Lang, Julie
    Pitts, Todd M.
    Lieu, Christopher H.
    Kopetz, Scott
    Davis, Sarah L.
    Jordan, Kimberly
    Bagby, Stacey M.
    Messersmith, Wells A.
    Pelanda, Roberta
    Eckhardt, S. Gail
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [3] Clinicopathological features of microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC) in Japanese patients.
    Kawazoe, Akihito
    Shitara, Kohei
    Noguchi, Masaaki
    Fukuoka, Shota
    Kuboki, Yasutoshi
    Bando, Hideaki
    Okamoto, Wataru
    Kojima, Takashi
    Doi, Toshihiko
    Ohtsu, Atsushi
    Yoshino, Takayuki
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [4] THE HUMANISTIC BURDEN OF MICROSATELLITE INSTABILITY-HIGH (MSI-H) COLORECTAL CANCER (CRC) AND METASTATIC CRC (MCRC) PATIENTS TREATED WITH SUBSEQUENT LINE THERAPY: A SYSTEMATIC REVIEW
    Kohn, C. G.
    Nguyen, E.
    Miller, J. D.
    Nwokeji, E.
    Laurie, M.
    Kamble
    Khan, T.
    Masood, A.
    Korytowsky, B.
    VALUE IN HEALTH, 2017, 20 (09) : A454 - A454
  • [5] Dostarlimab in advanced/recurrent (A/R) mismatch repair deficient/microsatellite instability-high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC): the GARNET study
    Oaknin, Ana
    Pothuri, Bhavana
    Gilbert, Lucy
    Sabatier, Renaud
    Ghamande, Sharad
    Gravina, Adriano
    Calvo, Emiliano
    Banerjee, Susana
    Mangan, Niamh
    Miller, Rowan E.
    Pikiel, Joanna
    Mirza, Mansoor R.
    Duan, Tao
    Zildjian, Sybil
    Zografos, Eleftherios
    Veneris, Jennifer
    Tinker, Anna V.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 133 - 134
  • [6] Clinical outcome of patients with microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC) treated with pembrolizumab.
    Sinicrope, Frank A.
    Chakrabarti, Sakti
    Eiring, Rachel
    Mitchelll, Jessica L.
    Finnes, Heidi D.
    Hubbard, Joleen Marie
    McWilliams, Robert R.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [7] Survival outcomes and functional results of VOLTAGE-A: Preoperative chemoradiotherapy (CRT) and consolidation nivolumab (nivo) in patients (pts) with both microsatellite stable (MSS) and microsatellite instability-high (MSI-H) locally advanced rectal cancer (LARC).
    Tsukada, Yuichiro
    Bando, Hideaki
    Inamori, Koji
    Wakabayashi, Masashi
    Togashi, Yosuke
    Koyama, Shohei
    Kotani, Daisuke
    Yuki, Satoshi
    Komatsu, Yoshito
    Homma, Shigenori
    Taketomi, Akinobu
    Uemura, Mamoru
    Kato, Takeshi
    Fukui, Makoto
    Kojima, Motohiro
    Sato, Akihiro
    Nishikawa, Hiroyoshi
    Ito, Masaaki
    Yoshino, Takayuki
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 108 - 108
  • [8] Dostarlimab in advanced/recurrent (AR) mismatch repair deficient/microsatellite instability-high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC): The GARNET study.
    Oaknin, Ana
    Pothuri, Bhavana
    Gilbert, Lucy
    Sabatier, Renaud
    Ghamande, Sharad A.
    Gravina, Adriano
    Calvo, Emiliano
    Banerjee, Susana N.
    Miller, Rowan
    Pikiel, Joanna
    Mirza, Mansoor Raza
    Duan, Tao
    Zildjian, Sybil
    Zografos, Eleftherios
    Veneris, Jennifer Taylor
    Tinker, Anna
    Powell, Matthew A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [9] Safety and antitumor activity of pembrolizumab in patients with advanced microsatellite instability-high (MSI-H) colorectal cancer: KEYNOTE-164
    Le, D.
    Kavan, P.
    Kim, T.
    Burge, M.
    Van Cutsem, E.
    Hara, H.
    Boland, P.
    Van Laethem, J.
    Geva, R.
    Taniguchi, H.
    Crocenzi, T.
    Sharma, M.
    Atreya, C.
    Diaz, L.
    Liang, L.
    Marinello, P.
    Dai, T.
    O'Neill, B.
    ANNALS OF ONCOLOGY, 2018, 29
  • [10] COMPARISON OF REAL-WORLD LATER-LINE TREATMENT OUTCOMES IN PATIENTS WITH MICROSATELLITE-INSTABILITY HIGH (MSI-H) VERSUS MICROSATELLITE-STABLE (MSS) METASTATIC COLORECTAL CANCER (MCRC) IN THE UNITED STATES (US)
    Dixon, M.
    Gu, J.
    VALUE IN HEALTH, 2022, 25 (07) : S313 - S314
12345